Muthoot Microfin Limited sees a credit rating action

The primary drivers were asset-quality and profitability recovery, not a demonstrated improvement in CAR. CareEdge cited:

• Gross NPA: improved from 4.8% as of March 31, 2025 to 3.7% as of June 30, 2026. ^[1]
• Credit costs: declined from 7.5% in FY25 to 3.0% in FY26; the Q1 FY27 annualised figure was reported at 2.3%. ^[2]
• Return on total assets: recovered from -1.6% in FY25 to 1.1% in FY26, with Q1 FY27 annualised RoTA reported at 2.0%. ^[2]
• Collection efficiency: increased by 477 basis points to 98.11% in Q2 FY27, supporting the recovery in portfolio performance. ^[1]

On capital, the cited evidence was that CAR remained a comfortable 24.9% as of June 30, 2026, versus a regulatory minimum of 15%; a prior-period CAR improvement was not quantified in the rating commentary. ^[3]

Funding-cost implication: the company’s cost of funds had already declined 20 basis points sequentially to 9.93% in Q2 FY27. ^[1] The positive outlook should improve lender confidence and potentially reduce the spread on incremental borrowings, particularly the proposed portion of the USD 50 million ECB programme covered by the rating action. ^[1] However, the cited company update does not provide a quantified forecast for incremental cost of funds for the balance of FY27. The defensible interpretation is therefore lower or contained marginal borrowing costs, rather than a stated target or guaranteed further decline; the rating itself remained CareEdge BB-, with only the outlook revised from Stable to Positive. ^[1]

Q2 FY27 performance was operationally strong, but it cannot be judged as above or below full-year internal guidance because no numeric FY27 guidance benchmark is reported in the update.

• Collection efficiency: 98.11% in Q2 FY27, improving by 477 basis points year on year.
• Disbursement growth: 28% year on year, reaching Rs 2,900 Crores. ^[1]

The appropriate read-through is therefore positive versus the prior-year operating baseline, not a confirmed beat against guidance. The update does not provide a full-year target for collection efficiency or disbursement growth, so “ahead of guidance” or “below guidance” cannot be established.

Localized-stress assessment: The reported metrics are company-wide. No region-wise collection efficiency or disbursement-growth figures are provided, so the resilience of performance in currently stressed geographies cannot be confirmed. CareEdge has separately identified geographical concentration and macroeconomic sensitivity as risks, with Tamil Nadu, Kerala and Bihar together accounting for roughly 50% of AUM, but it does not provide Q2 operating metrics for those regions. ^[3]

Implication: The 98.11% collection efficiency suggests broad portfolio improvement, while 28% disbursement growth indicates that growth has remained strong despite the stress backdrop. However, the key unresolved issue is whether these aggregate figures are being supported by healthy collections and disciplined underwriting in the affected regions, rather than by stronger performance elsewhere.

Verdict: Muthoot Microfin shows a 22.00% YoY AUM growth rate in Q2 FY27, accelerating from 18.00% YoY in Q1 FY27—a derived improvement of 4.00 percentage points ^{[2] [1]}. Its rating direction is also improving, but there is no defensible industry-average benchmark because comparable Q2 FY27 AUM growth, ratings and non-MFI mix data for Satin, Fusion, Spandana and CreditAccess could not be confirmed.

Muthoot Microfin versus the named listed peer set

Portfolio-mix interpretation

The 31.00% figure should not be labelled as Muthoot’s exact non-MFI share. The company reported a JLG/non-JLG mix of 69:31, rather than a separately defined MFI/non-MFI split ^[1]. The non-JLG share therefore rose by 14.00 percentage points from March to September 2026, indicating meaningful diversification away from the core JLG model.

Muthoot separately reported an SME individual-loan portfolio of Rs 4,164 Crores. That equals approximately 27.17% of Q2 FY27 AUM, calculated as Rs 4,164 Crores divided by Rs 15,323 Crores ^[1]. This is a product-specific share, not the total non-MFI portfolio, because other individual and secured products—including loans against property and gold-loan co-lending—may also sit outside the core JLG book.

Analyst read: Muthoot’s disclosed growth and diversification trend is positive on a standalone basis, and the rating outlook has improved. However, it cannot yet be described as above or below the listed-MFI industry average on non-MFI mix: the peer-specific average is not publicly available on a comparable Q2 FY27 basis, and Muthoot’s 31.00% non-JLG ratio is not definitionally identical to non-MFI share.